Evaluation of the optimal values of cholesterol of high density lipoproteins in a cohort of men aged 40-59 with myocardial infarction (according to 30-year monitoring of the status of life)

Aim. To establish connection between the functions of 30-year survival rate and concentration of cholesterol high density lipoproteins (C-HDL) in men aged 40-59 years with a past history of a myocardial infarction (MI) and relying on the obtained data to determine the optimal level of C-HDL for the specified cohort.

Material and methods. The study includes 141 patients who have had MI more than 6 months ago and observed in clinics of Metallurgical district of the city of Chelyabinsk within the third group of dispensary register. Specified MI cases refer to types 1, 2 of the Third universal definition of MI. The initial stage of study of the target group of men who have a past history of MI lasted from 03.06.1974 to 24.11.1975. Observation points were 0 and 30 years. The endpoint was death. Information about the dead established during the annual monitoring of the status of life. During the observation period 130 persons/92,2% died. Evaluation of survival was carried out according to the method of Kaplan-Meier, based on which a Cox regression model was built with the inclusion of successively higher minimum level of C-HDL, so that survival curves were significantly different. 95% confidence intervals were determined. The confidence bands of survival functions were built on the basis of on non-parametric Kolmogorov-Smirnov test.

Results. The analysis of the function of 30-year survival in men aged 40-59 with past history of MI, depending on the level of HDL-C showed: the presence of statistically significant relationships between survival and levels of HDL-C. Optimal concentrations of HDL cholesterol for survival were the values of HDL-C ≥2,0 mmol/l. Statistically significant periods of survival differences are shown on survival curves at different levels of HDL-C. The possibility of prediction of survival of each patient to a certain time depending on the level HDL-C is determined. Initial levels of HDL-C determine the beginning, duration, end of periods of statistically significant survival differences on survival curves.

Conclusion. The analysis of 30-year monitoring of the life status of cohort of men aged 40-59 with past history of MI showed a statistically significant dependence of survival on the initial level of HDL-C. The initial concentration of HDL-C are optimal for survival of indicated cohorts of men. HDL-C levels of 2,0-2,9 mmol/l can serve as a therapeutic target for men aged 40-59 with a past history of MI. The functions of 30-year survival in the cohort of middle-aged men who underwent MI, allow to determine the probability of survival of patients with this level of HDL-C to certain time.

1. Matthew N, Ramachandran SV. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison with International Guidelines. Circulation. 2016;133(18):1795-806. doi:10.1161/CIRCULATIONAHA.116.021407.

2. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013;9:617-70. doi:10.2147/VHRM.S37119.

3. Lin GM, Li YH, Lin CL, et al. Low high-density lipoprotein cholesterol and low/ normal body mass index are associated with increased mortality in coronary artery disease patients in Taiwan. Circ J. 2013;77(8):2079-87. doi:10.1253/circj.CJ-12-1511.

4. Di Angelantonio E, Gao P, Pennells L, et al.; Emerging Risk Factors Collaboration. Lipidrelated markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499- 506. doi:10.1001/jama.2012.6571.

5. Ge P, Dong C, Ren X, et al. The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. PLoS One. 2015;10(12):e0144104. doi:10.1371/journal.pone.0144104.

6. Thygesen K, Alpert JS, Jaffe AS, et al. The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/ American Heart Association (AHA)/World Heart Federation (WHF). Task Force for the Universal Definition of Myocardial Infarction. JACC. 2018;72(18):2231-64. doi:10.1016/j.jacc.2018.08.1038.

7. Oganov RG, Boytsov SA. Editorial a. Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.

8. Belov VV, Menshchikov AA. Survival of cogorts of cardiac patients and healthy men aged 40-59 years: the 30-year follow-up data. Cardiovascular Therapy and Prevention. 2013;12(2):74-9. (In Russ.) doi: 10.15829/1728-8800-2013-2-74-79.

9. Hirata A, Okamura T, Sugiyama D, et al. NIPPON DATA90 Research Group. The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. J Atheroscler Thromb. 2016;23(7):800-9. doi:10.5551/jat.33449.

10. Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation. 2013;128(10):1112- 21. doi:10.1161/CIRCULATIONAHA.113.002683.

11. Klempfner R, Erez A, Sagit BZ, et al. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016; 9(2):100-8. doi:10.1161/CIRCOUTCOMES.115.002104.

12. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(5):484-525. doi:10.1016/j.jacl.2013.08.001.

13. Ahmed HM, Miller M, Nasir K, et al. Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016;183(10): 875-83. doi:10.1093/aje/kwv305.

14. Sharif S, van der Graaf Y, Nathoe H M et al. SMART Study Group. HDL cholesterol as a residual risk factor for vascular events end all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424-30. doi:10.2337/dc16-0155.